MAP3K8/Tpl2/COT Antibody

Western Blot: MAP3K8/Tpl2/COT Antibody [NBP1-62178] - 50-60 ug of rat midbrain protein. Primary antibody is diluted with 1:500 in DiluOBuffer. Apparent MW of MAP3K8 is 57 KDa.

Immunohistochemistry-Paraffin: MAP3K8/Tpl2/COT Antibody [NBP1-62178] - 1:1000 dilution in IHC Blocking Buffer. DAB (brown) staining and Hematoxylin QS (blue) counterstain. 40x MAGNIFICATION. FFPE section.

• Reactivity: Hu, Mu, Rt
• Applications: WB, ELISA, IHC, IP
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated

MAP3K8/Tpl2/COT Antibody Summary

• Immunogen: Synthetic peptides corresponding to unique epitope on MAP3K8. The peptide sequence was selected from C-terminal-region, amimo acids 365-467. This peptide was covalently modified post-synthetically to achieve desired antigenicity.
• Specificity: This antibody detects a single band of approximately 57kDa in PC-MAP3K8 samples
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: MAP3K8
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA < 1:10000
  • Immunohistochemistry 1:50-1:150
  • Immunohistochemistry-Paraffin 1:50-1:150
  • Immunoprecipitation 1:200
  • Western Blot > 1:500
• Application Notes: By western blot this antibody detects a single band of approximately 57kDa in PC-MAP3K8 samples.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Tris/Glycine buffer, pH 7.4-7.8, HEPES,BSA 0.5%, glycerol 30%.
• Preservative: 0.02% Sodium Azide
• Purity: Immunogen affinity purified

Alternate Names for MAP3K8/Tpl2/COT Antibody

• Cancer Osaka thyroid oncogene
• c-COT
• cot (cancer Osaka thyroid) oncogene
• COT
• COTMEKK8
• EC 2.7.11.25
• EST
• ESTF
• ESTFLJ10486
• Ewing sarcoma transformant
• MAP3K8
• mitogen-activated protein kinase kinase kinase 8
• Proto-oncogene c-Cot
• proto-oncogene serine/threoine protein kinase
• Serine/threonine-protein kinase cot
• TPL2
• Tpl-2
• Tumor progression locus 2
• tumor progression locus-2

Background

Tumor progression locus 2 (Tpl2) is a hematopoietically expressed serine-threonine protein kinase critical in innate immunity linking TOLL receptor (TLRs) to TNF production via activation of its extracellular signal regulated kinase (ERK) kinase (1). MAP3K8 is shown to activate IkappaB kinases, and thus induce the nuclear production of NF-kappaB. This kinase was also found to promote the production of TNF-alpha and IL-2 during T lymphocyte activation. Gram positive bacterial infection like Listeria monocytogenes is capable of activating both TLRs and non TLR particle recognition receptors (PRRs) and cause MAP3K8 dependent production of TNF, IFN and IL2 (2). MAP3K8 activation also promotes Androgen depletion-independent prostate cancer growth (3). MAP3K8 is selectively involved in inflammatory cytokine-induced ERK1/2 activation in adipocytes and is implicated in dysfunction of adipose tissue in obesity (4). MAP3K8 was identified as a signaling molecule that is required for the regulation of critical function of T helper cells in promoting expression of transcription factors that derived optimal Th1 differentiation (5). MAP3K8 is expressed in immune cells whilst, over expression of MAP3K8 in PBMC causes dys-regulation og IFN-Y, STS4, IL-12 and many other cytokines (6). MAP3K8 gene is located on chromosome 10p11.23, in humans; MAP3K8 is approximately a 57Da protein (467 amino acids). In rat and mouse this protein has similar molecular weights with some conservative substitutions. MAP3K8 gene may also utilize a downstream in-frame translation start codon, and thus produce an isoform containing a shorter N-terminus. The shorter isoform has been shown to display weaker transforming activity. The MAP3K8 antibodies were generated using peptide corresponding to the human MAP3K8 protein. MAP3K8 antibodies are affinity purified over immobilized antigen based affinity chromatography, and the purified immunoglobulins are stabilized in antibody stabilization buffer.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for MAP3K8/Tpl2/COT Antibody (NBP1-62178)(4)

Publications using NBP1-62178

• Jeong JH, Bhatia A, Toth Z, Oh S, Inn KS, Liao CP, Roy-Burman P, Melamed J, Coetzee GA, Jung JU. TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS One;6(1):e16205. 2011-01-18 [PMID: 21267413]
• Mielke LA, Elkins KL, Wei L, Starr R, Tsichlis PN, O'Shea JJ, Watford WT. Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J Immunol;183(12):7984-93. 2009-12-15 [PMID: 19933865]
• Jager J, Gremeaux T, Gonzalez T, Bonnafous S, Debard C, Laville M, Vidal H, Tran A, Gual P, Le Marchand-Brustel Y, Cormont M, Tanti JF. Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes;59(1):61-70. 2010-01-01 [PMID: 19808894]
• O'Neill LA. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity;29(1):12-20. 2008-07-18 [PMID: 18631453]

Bioinformatics

• Gene Symbol: MAP3K8